In reference to Current Report No. 39/2017 dated 24 August 2017 and subsequent current reports regarding initial results of the MabionCD20 clinical trial carried out on patients treated for rheumatoid arthritis _RA_, the Management Board of Mabion S.A. _The "Company"_ hereby informs that on March 22, 2018 an external entity contracted to analyse the results regarding responses to treatment of RA patients provided it with a confirmation that the status of results of the clinical trial reported in the aforementioned reports, after a detailed verification, has been changed from "initial" to "final".

Hence the positive assessment of results of the clinical trial remained unchanged.

The final versions of reports will be attached to the marketing authorisation application _MAA_. The Company notes that positive results of the trial do not guarantee that the product will be approved by the European Medicines Agency _EMA_.